Pinned straw:
@Arizona @Schwerms @Nnyck777 @NewbieHK as far as I know, there is no new information in the market beyond i) their initial sales data, ii) the tariff response and iii) MC standing aside due to health.
I'm going to put forward 2 possible explanations, stating up front that I don't know which one, if either, is valid:
EXPLANATION 1
According to my marketscreener.com report, there has been one analyst dropping coverage very recently. (see below)
Prior to early April, Euroz Harley and Evans and Partners has PT of $0.80 and $0.50, respectively, for an average of $0.65.
If the $0.80 PT is the graph below is EH (which makes sense because the EH updates appear in the MarketScreener.com newsfeed) then the picture below would imply that they have dropped coverage. However, their $0.80 PT still appears as live in the tradingview.com analyst summary. So, this doesn't make sense.
So, perhaps (for some reason) EH has stopped feeding news aggregators like marketscreener.com and Simply Wall Street. Remember that Simply Wall Street is algorithmic, so if it stopped getting a feed, and was left with the less optimistic forecast, this could have the impact on the reported financial forecast as showing the breakeven pushing out to FY27. Even though no-one (in that scenario) would actually have changed their forecast.
So my first exaplanation is that some market participants might be reacting to data integrity issues in several the of the aggregation services.
As I said, I don't know what is factually correct here, and I am just trying to make sense of things.
Explanation 2
Hot money getting impatient and supply of shares due to short selling.
Following relative quiet after the initial sales data, there has perhaps been some short term money taking profits from the cap. raise discount at $0.33 or simply some investors getting impatient. As one of you said, perhaps there was an expectation of a quick multibagger. Once the short term chart starts to turn, the stock starts appear on a number of technical filters, and technical trading "talking heads" as "sell". This happens more often than not with biotechs.
We have also recently see some significant short interest building up(see below), and that will be increasing supply at a time of no new information - which would exacerbate downwards price pressure.
My Conclusion
I am pretty much ignoring all of this, since, as far as I can see, it is based on no actual information.
What I am interested in is whether $BOT issues a revenue trading update for 1H. Within a week or two - based on script weekly run rates - they'd be in a position to give a pretty tight revenue number, and publish the weekly charts for number of scripts, and number of prescribers. This would add another 8 or 9 weeks of data to the initial series we had. From my perspectively, such information will be hugely valuable as it would allow us to see whether:
a) They remain in a accelerating phase of the S-curve (potentially a massive catalyst for the SP)
b) Whether they are entering the "linear' phase of the S-curve (a big catalyst from where we are in today's SP)
c) Whether momentum is stalled. .... trickier.
I don't know whether $BOT observe the period end "blackout". Becuase if they do, such a trading update will need to come out in the next week or maybe two.
In any event, all I care about is real performance data. As for the rest, the market will do what the market will do.
Disc: Held.
Feels to me like some of the short sellers closing out, this drop has gotten a bit out of hand, the volume has been big over the last week.
I got some more today at 29 and 30..
Fundamentals to me are unchanged but it does hurt to look at right now.
I've done some work on being cash flow positive and at the current rate it's Q4 this calendar year assuming we get near $100m annual costs and stay on the current trajectory we last saw and including payment lag from the insurers.
I'll double check my numbers and post it tonight if I get a chance.
Maybe some tariff and MFN related selling but a minimal and no affect.
Would be easy to sell if you didn't have strong conviction with the recent drops from the high.
The same site that had this as fair value of $7.00? I am dubious. This sell off feels orchestrated! Below pre FDA approval levels. BOT was already well ahead of Euroz Hartley’s prediction if it stays on track.